Search | Clinical Trials Finder

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: aldesleukin, recombinant interferon alfa; Biological
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1999
U.S. locations: 5
States / cities: Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: MART-1 antigen, gp100:209-217(210M) peptide vaccine, therapeutic autologous dendritic cells, tyrosinase peptide; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 16 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: Los Angeles, California • Ann Arbor, Michigan

Conditions: Prostate Cancer Metastatic
Interventions: PROSTVAC-V, PROSTVAC-F, GM-CSF, GM-CSF Placebo, Placebo; Biological · Drug · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 84
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Berkeley, California + 68 more

Conditions: HIV Infections, Cytopenias
Interventions: Epoetin alfa; Drug
Lead sponsor: Ortho Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: Acquired Immunodeficiency Syndrome, Burning Mouth Syndrome, HIV Infection
Interventions: Thalidomide; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma
Interventions: SB-485232; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Santa Monica, California + 9 more

Conditions: LAD1
Interventions: Ustekinumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia, Myeloid, Acute
Interventions: Granulocyte colony-stimulating factor (G-CSF), Cladribine, Cytarabine, All-Trans Retinoic Acid (ATRA), Midostaurin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Sclerosis
Interventions: Interferon beta 1a, oral doxycycline; Drug
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Lymphoma
Interventions: filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, pegaspargase, prednisone, thioguanine, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 20 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2007
U.S. locations: 30
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 24 more

Conditions: Transfusions
Interventions: NPO, Control group: continue feedings; Other
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 3 Days to 6 Months
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Childhood Germ Cell Tumor, Ovarian Cancer, Teratoma
Interventions: carboplatin, etoposide, ifosfamide, paclitaxel, thiotepa, autologous hematopoietic stem cell transplantation, Mesna, filgrastim; Drug · Procedure · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 10 Years to 69 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions: doxorubicin hydrochloride, cyclophosphamide, paclitaxel, filgrastim, capecitabine, methotrexate, vinorelbine tartrate, needle biopsy, therapeutic conventional surgery, immunohistochemistry staining method, trastuzumab, tamoxifen citrate, letrozole, laboratory biomarker analysis; Drug · Biological · Procedure + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: IFN-Gamma Therapy, CGD Gene Mutation, CGD Response to IFNg, CGD - Chronic Granulomatous Disease, Immunodeficiency Disease
Interventions: IFN-gamma; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
Interventions: Rituximab, Conditioning chemotherapy, TMS, FLAG, EPOCH-F, Hematopoietic stem cell transplant, Palifermin, Acetaminophen, Diphenhydramine, Prednisone, Epinephrine, IV Saline, ECG, ECHO, MUGA, DEXA, CT chest, PET, MRI, BM aspirate, BM biopsy, Lumbar puncture; Biological · Drug · Procedure + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Breast Cancer
Interventions: aldesleukin, recombinant interferon gamma, carboplatin, cyclophosphamide, cyclosporine, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Burkitt Lymphoma, Lymphoma, Large-Cell, Diffuse, Lymphoma, Small Noncleaved-Cell
Interventions: granulocyte-macrophage colony stimulating factor (GM-CSF); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI); Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 45 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Kidney Cancer
Interventions: PEG-interferon alfa-2b, GM-CSF, thalidomide; Biological · Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 120 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Myelogenous Leukemia, Lymphoblastic Leukemia
Interventions: Tacrolimus, Sirolimus, G-CSF, Antithymocyte globulin, Thymoglobulin, Fludarabine, Melphalan; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Melanoma (Skin)
Interventions: Detox-B adjuvant, recombinant interferon alfa; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 27
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 21 more

Conditions: Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelofibrosis, Polycythemia Vera
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement, Piperine Extract (Standardized), Placebo Administration, Questionnaire Administration; Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Burkitt's Lymphoma, Burkitt'S-like Lymphoma
Interventions: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, G-CSF, Cytarabine, Methotrexate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aplastic Anemia
Interventions: G-CSF, Apheresis; Drug · Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

Vaccine Therapy in Treating Patients With Metastatic Melanoma

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

Thalidomide to Treat Oral Lesions in HIV-Infected Patients

Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML

Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis

Combination Chemotherapy in Treating Children With Lymphoma

Impact of Feeding on Pro-Inflammatory Cytokine Response in Neonates Receiving a RBC Transfusion

Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer

Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer

Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus

Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission